Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8861555 | 0.98 | RECQL (0.32) | RECQLALDH1A1TSHR | |
| SCHEMBL28090497 | 0.81 | ALOX15 (0.36) | RECQLALDH1A1TSHR | |
| SCHEMBL9333024 | 0.81 | RECQL (0.41) | RECQLALDH1A1TSHR | |
| SCHEMBL1742070 | 0.80 | RECQL (0.38) | RECQL | |
| SCHEMBL2726401 | 0.79 | RECQL (0.30) | RECQL | |
| SCHEMBL2396704 | 0.79 | RECQL (0.40) | RECQLALDH1A1TSHR | |
| SCHEMBL4332189 | 0.75 | RECQL (0.31) | RECQLALDH1A1TSHR | |
| SCHEMBL4326668 | 0.75 | ALDH1A1 (0.36) | ALDH1A1TSHR | |
| SCHEMBL2305604 | 0.73 | KDM6B (0.31) | RECQL | |
| SCHEMBL19327562 | 0.73 | TSHR (0.32) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3194964-B1 | MULTIFUNCTIONAL PROTEIN MOLECULAR WEIGHT STANDARDS | LI COR INC (US) | 2021-10-27 | — | — | EP | claimed |
| US-20100003701-A1 | COVALENT MODIFICATION AND CONJUGATION OF LUCIFERASE | CARDIOGENICS INC. (CA) | 2010-01-07 | — | — | US | claimed |
| US-20070254311-A1 | Covalent modification and conjugation of luciferase | CARDIOGENICS INC. (CA) | 2007-11-01 | — | — | US | claimed |
| US-20250340672-A1 | VL ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS | REGENERON PHARMA (US) | 2025-11-06 | — | — | US | disclosed |
| US-12305205-B2 | AprL-clade protease variants and uses thereof | DANISCO US INC. (US) | 2025-05-20 | — | — | US | disclosed |
| WO-2025054327-A1 | CONSTRUCTS, COMPOSITIONS, AND METHODS FOR REDUCING HYPERSENSITIVITY REACTIONS TO THERAPEUTIC AGENTS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025049848-A2 | PROTEASES AND ALDC ENZYMES FOR BEER HAZE AND DIACETYL REDUCTION | INTERNATIONAL N&H DENMARK APS (DK) | 2025-03-06 | — | — | WO | disclosed |
| US-20240301383-A1 | AprL-CLADE PROTEASE VARIANTS AND USES THEREOF | DANISCO US INC (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240124613-A1 | VL ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS | REGENERON PHARMA (US) | 2024-04-18 | — | — | US | disclosed |
| US-20230295601-A1 | ALDC PRODUCTION METHODS | INTERNATIONAL N&H DENMARK APS (DK) | 2023-09-21 | — | — | US | disclosed |
| EP-4219704-A2 | APRL-CLADE PROTEASE VARIANTS AND USES THEREOF | Danisco US Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20040185058-A1 | Composite superimmunogen for bi-functional vaccine use for the treatment of illnesses associated with a stromal tissue disorder | NEOVACS (FR) | 2004-09-23 | — | — | US | disclosed |
| WO-2004056970-A2 | CHEMO-ENZYMATIC PROCESS FOR PROTEOME-WIDE MAPPING OF POST-TRANSLATIONAL MODIFICATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-07-08 | — | — | WO | disclosed |
| EP-1427441-A2 | COMPOSITE SUPERIMMUNOGEN FOR BI-FUNCTIONAL VACCINE USE FOR THE TREATMENT OF ILLNESSES ASSOCIATED WITH A STROMAL TISSUE DISORDER | NEOVACS (FR) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003013593-A2 | COMPOSITE SUPERIMMUNOGEN FOR BI-FUNCTIONAL VACCINE USE FOR THE TREATMENT OF ILLNESSES ASSOCIATED WITH A STROMAL TISSUE DISORDER | NEOVACS (FR) | 2003-02-20 | — | — | WO | disclosed |
| US-20030003106-A1 | Use of protein derived from cancer cells, cells infected by a virus or immune cells or an inactive fragment thereof, protein being initially an immunosuppressive and/or angiogenic protein for obtaining medicines to provide mucosal immunity | NEOVACS (FR) | 2003-01-02 | — | — | US | disclosed |
| EP-1237573-A1 | USE OF INACTIVATED IMMUNOSUPPRESSIVE OR ANGIOGENIC IMMUNOGENIC PROTEINS FOR PRODUCING SECRETORY IGA'S | NEOVACS (FR) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001043771-A1 | USE OF INACTIVATED IMMUNOSUPPRESSIVE OR ANGIOGENIC IMMUNOGENIC PROTEINS FOR PRODUCING SECRETORY IGA'S | NEOVACS (FR) | 2001-06-21 | — | — | WO | disclosed |
| US-5928667-A | Drug delivery device and method for employing the same | UNIVERSITY OF MARYLAND (US) | 1999-07-27 | — | — | US | disclosed |
| US-5788959-A | Drug delivery device and method for employing the same | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 1998-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040185058-A1 | Composite superimmunogen for bi-functional vaccine use for the treatment of illnesses associated with a stromal tissue disorder | TSLP, CXCL12, PLA2G12A | RECQL 1196/4885ALDH1A1 2171/4885TSHR 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.